StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$30.20−2.34 (-7.19%)

Close on Nov 20, 2026Market cap $1.03BP/E –Yield –

Nektar Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Nektar Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$208.68M. For fiscal 2025 it was -$208.68M. The highest annual figure on record is $703.98M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$208.68M–
FY2024Dec 31, 2024-$177.18M–
FY2023Dec 31, 2023-$193.47M–
FY2022Dec 31, 2022-$309.68M–
FY2021Dec 31, 2021-$427.65M–
FY2020Dec 31, 2020-$320.55M–
FY2019Dec 31, 2019-$354.97M-150.4%
FY2018Dec 31, 2018$703.98M–
FY2017Dec 31, 2017-$90.09M–
FY2016Dec 31, 2016-$123.42M–
FY2015Dec 31, 2015-$84.28M–
FY2014Dec 31, 2014-$151.98M–
FY2013Dec 31, 2013-$42.62M–
FY2012Dec 31, 2012-$140.34M–
FY2011Dec 31, 2011-$123.46M–
FY2010Dec 31, 2010-$87.33M-474.0%
FY2009Dec 31, 2009$23.35M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$64.98M–
Q3 FY2025Sep 30, 2025-$48.88M–
Q2 FY2025Jun 30, 2025-$45.78M–
Q1 FY2025Mar 31, 2025-$49.06M–
Q4 FY2024Dec 31, 2024-$46.65M–
Q3 FY2024Sep 30, 2024-$44.60M–
Q2 FY2024Jun 30, 2024-$37.89M–
Q1 FY2024Mar 31, 2024-$48.05M–
Q4 FY2023Dec 31, 2023-$47.28M–
Q3 FY2023Sep 30, 2023-$42.15M–
Q2 FY2023Jun 30, 2023-$51.69M–
Q1 FY2023Mar 31, 2023-$52.35M–
Q4 FY2022Dec 31, 2022-$58.22M–
Q3 FY2022Sep 30, 2022-$83.07M–
Q2 FY2022Jun 30, 2022-$75.77M–
Q1 FY2022Mar 31, 2022-$92.63M–
Q4 FY2021Dec 31, 2021-$157.43M–
Q3 FY2021Sep 30, 2021-$104.07M–
Q2 FY2021Jun 30, 2021-$86.18M–
Q1 FY2021Mar 31, 2021-$79.96M–
Q4 FY2020Dec 31, 2020-$100.39M–
Q3 FY2020Sep 30, 2020-$54.59M–
Q2 FY2020Jun 30, 2020-$86.60M–
Q1 FY2020Mar 31, 2020-$78.98M–
Q4 FY2019Dec 31, 2019-$128.89M–
Q3 FY2019Sep 30, 2019-$73.96M–
Q2 FY2019Jun 30, 2019-$65.57M-106.9%
Q1 FY2019Mar 31, 2019-$86.54M–
Q4 FY2018Dec 31, 2018-$126.24M–
Q3 FY2018Sep 30, 2018-$73.23M-179.5%
Q2 FY2018Jun 30, 2018$956.90M–
Q1 FY2018Mar 31, 2018-$53.45M–
Q4 FY2017Dec 31, 2017-$82.79M–
Q3 FY2017Sep 30, 2017$92.14M–
Q2 FY2017Jun 30, 2017-$60.78M–
Q1 FY2017Mar 31, 2017-$38.66M–
Q4 FY2016Dec 31, 2016-$55.06M–
Q3 FY2016Sep 30, 2016-$27.87M–
Q2 FY2016Jun 30, 2016-$15.16M–

More Nektar Therapeutics figures

See a number that looks wrong?